Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service, Personnel

BioLabs Appoints Dr. Nina Dudnik Chief Business Officer


BioLabs, the definitive growth partner for science-based entrepreneurs, today announced it has named Dr. Nina Dudnik the new Chief Business Officer. Dudnik, a former BioLabs board member, leader in innovation and entrepreneurship and inspirational keynote speaker, brings to BioLabs a wealth of expertise around growing an entrepreneurial and innovation venture.

"We are excited to welcome Nina as our new Chief Business Officer at BioLabs," said Johannes Fruehauf, CEO of BioLabs. "Her experience facilitating the advancement of R&D in dozens of different countries world-wide, paired with an entrepreneurial can-do spirit and extensive track record in negotiation and government relations will be a tremendous benefit to BioLabs as we enter this next phase of our growth. Nina will join a team dedicated to supporting and helping founders advance their science, grow their business, and have a lasting impact on patients around the world."

Previously a member of BioLabs' Board of Directors, Dudnik was hired to manage and expand BioLabs' business development, sponsorship, and partner management functions at a time where BioLabs is launching its international expansion with sites opening in Germany and in France in 2021/22. She brings over 15 years of experience translating vision into social and business impact. Dudnik received her B.S. in Biochemistry from Brown, PhD in Biomedical Sciences from Harvard, and was a researcher and Fulbright Scholar before becoming the Founder and CEO of Seeding Labs. She led the award-winning non-profit until 2019, investing in research and innovation in 34 countries and building partnerships with universities, corporations, and governments worldwide. Most recently, Dudnik worked in corporate strategy and government affairs at MilliporeSigma.

"I am excited to be a part of BioLabs and work within their culture of innovation and clear commitment to the success of its entrepreneurs," said Dudnik. "Working with BioLabs is a great opportunity not only for me, but also to help scientists accelerate and grow within this life-science ecosystem. I look forward to empowering entrepreneurs with an amazing team behind me."

About BioLabs

BioLabs is the definitive growth partner for science-based entrepreneurs; empowering entrepreneurs to accelerate their science, grow their business and have a lasting impact on the world. The BioLabs difference is in their sector-defining ecosystem: delivering best-in-class lab space, essential business services, a powerful network of innovators and guides who offer "been-there" insight, and site teams with unparalleled experience guiding founders through the complexities of growing a biotech company. BioLabs' centers are in key innovation hubs across North America and opening in Europe in 2021. Follow BioLabs on Twitter (@BioLabs) and on Facebook and LinkedIn.


These press releases may also interest you

at 06:50
Merck , known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for the first-line treatment of patients with...

at 06:50
The "Global Oncolytic Virus Therapy Market Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The market is anticipated to garner a revenue of around USD 1060 Million by the end of 2028, up from a revenue of close to USD 160...

at 06:50
BD (Becton, Dickinson and Company) , a leading global medical technology company, today issued the following statement regarding testing for the COVID-19 Omicron variant of concern....

at 06:35
ImmunoGen Inc. , a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine...

at 06:35
NovaQuest Capital Management, LLC ("NovaQuest"), a biopharma and life sciences investment firm specializing in human and animal health investing, and TechAccel LLC ("TechAccel"), a technology and venture development organization, announced today that...

at 06:35
AstraZeneca and Merck , known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA) for...



News published on 28 october 2021 at 09:06 and distributed by: